Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

The Chronic Obstructive Pulmonary Disease Treatment Market size was valued at USD 21.66 Billion in 2023 and the total Chronic Obstructive Pulmonary Disease Treatment revenue is expected to grow at a CAGR of 5.5% from 2024 to 2030, reaching nearly USD 31.51 Billion.

The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. To know about the Research Methodology   :- Request Free Sample Report

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics. There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution. Exposure to second-hand or passive smoking. Smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status and dietary factors, which lead directly or indirectly to COPD.

Increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and incidence of respiratory diseases i.e., asthma, and cystic fibrosis is expected to drive the market growth during the forecast period. However, emerging markets and growth in online marketing channel offers opportunities for the market. New drug development by market players through collaborations and increase in research and development expenditure are anticipated to drive the global market. Propeller Health and Novartis Pharma AG entered into collaboration to develop a custom add-on sensor for the Breezhaler inhaler, a device indicated for COPD treatments.

Rise in number of public and private organizations is another major factor propelling the growth of COPD Treatment market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology. Such initiatives are in turn expected to increase the market in developing regions, thereby boosting overall market growth.

There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD. Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth.

By drug type, bronchodilators are further categorized as Short-Acting Bronchodilators and Long- Acting Bronchodilators. These medications work quickly to relax the muscles around your airways and ease symptoms like coughing and shortness of breath. The effects last for about 6 to 12 hours.

North America dominates Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market because of rise in collaborations and high investments in healthcare sector. Globally the market for COPD is increasing rapidly. The major factor that derives the growth of COPD is the increasing growth in smoking in adults.

The objective of the report is to present comprehensive analysis of Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding  dynamics, structure by analyzing the market segments, and project the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market make the report investor’s guide.

Chronic Obstructive Pulmonary Disease (COPD) Treatment market Scope : Inquire before buying

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Key players

1. AstraZeneca,
2. Boehringer Ingelheim Pharmaceuticals, Inc.,
3. GlaxoSmithKline plc,
4. Novartis AG,
5. CHIESI Farmaceutici S.p.A.,
6. Sunovion Pharmaceuticals, Inc.
7. Teva Pharmaceutical Industries Ltd,
8. Mylan N.V.
9. Orion Corporation.
10.Abbott
11.Dr. Reddy's Laboratories Ltd
12.F. Hoffmann-La Roche Ltd
13.Forest Labs
14.GSK
15.Galapagos NV
16.Merck
17.Mundipharma
18.Nycomed
19.Orexo
20.Pfizer Inc
21.Roche
22.Almirall
23.Astellas Pharma
24.Circassia Pharmaceuticals

Frequently Asked Questions:

1. Which region has the largest share in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Ans: North America region holds the highest share in 2023.

2. What is the growth rate of Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Ans: The Global Market is growing at a CAGR of 5.5% during forecasting period 2024-2030.

3. What is scope of the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global market?
Ans: The important key players in the Global Market are – AstraZeneca,, Boehringer Ingelheim Pharmaceuticals, Inc.,, GlaxoSmithKline plc,, Novartis AG,, CHIESI Farmaceutici S.p.A.,, Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd,, Mylan N.V., Orion Corporation., Abbott, Dr. Reddy's Laboratories Ltd, F. Hoffmann-La Roche Ltd, Forest Labs, GSK, Galapagos NV, Merck, Mundipharma, Nycomed, Orexo, Pfizer Inc, Roche, Almirall, Astellas Pharma, and Circassia Pharmaceuticals

5. What was the Global Chronic Obstructive Pulmonary Disease Treatment Market size in 2023?
Ans: The Global Chronic Obstructive Pulmonary Disease Treatment Market size was USD 21.66 Billion in 2023.